SCHEMBL5366573

SCHEMBL5366573

COc1ccc(Br)c(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)c1O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52
MOGAT2 Q3SYC2 5/20 0.51
MGAT2 Q10469 2/20 0.48
BRD4 O60885 5/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
LRRK2 Q5S007 1/20 0.42
BRD2 P25440 1/20 0.41
LMNA P02545 1/20 0.41
PLK4 O00444 1/20 0.41
PLK1 P53350 1/20 0.41
PRKDC P78527 1/20 0.40
AURKA O14965 1/20 0.40
RAF1 P04049 1/20 0.40
NOX4 Q9NPH5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357883 0.87 MOGAT2 (0.51) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5367388 0.86 MOGAT2 (0.51) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5366974 0.86 MOGAT2 (0.51) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5364990 0.85 MOGAT2 (0.56) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5364674 0.85 MOGAT2 (0.52) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL7135582 0.85 MEN1 (0.53) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5363156 0.85 MOGAT2 (0.55) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5358042 0.84 NTRK1 (0.51) MAPK1L3MBTL1LRRK2LMNAPLK4
SCHEMBL5364979 0.84 MEN1 (0.61) MEN1ALOX15MAPK1KMT2AMOGAT2
SCHEMBL5369908 0.83 MOGAT2 (0.52) MEN1ALOX15MAPK1KMT2AMOGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MEN1 3855/4885ALOX15 748/4885MAPK1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.